Nurix Therapeutics, Inc. Share Price & Technical Analysis
NRIX · $17.50 (-0.17%)
Healthcare / Biotechnology
$17.50
-0.17%
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell m…
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
5% return in May, 10% avg return in past 3 year May month.
-4% return in 2026, 42% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -13% | -3% | 1% | 7% | 5% | – | – | – | – | – | – | – | -4% |
| 25 | 3% | -21% | -23% | -3% | -7% | 3% | -1% | -16% | -1% | 39% | 39% | 10% | 22% |
| 24 | -24% | 57% | 19% | -18% | 31% | 29% | 5% | 15% | -10% | 9% | -10% | -18% | 83% |
| 23 | 11% | -24% | -4% | 8% | 5% | -1% | -3% | -11% | -8% | -28% | 11% | 66% | 21% |
| 22 | -36% | -13% | -14% | -22% | -8% | 26% | 27% | 0% | -17% | -5% | -5% | -12% | -78% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Strong · Strong
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.63B
P/E ratio
—
52W high
$22.50
52W low
$8.20
Volume
10,53,788
Beta
1.88
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Nurix Therapeutics, Inc. share price today?
- Nurix Therapeutics, Inc. (NRIX) last traded around $17.50 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does NRIX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for NRIX. Download the app for real-time alerts.
- How can I analyze Nurix Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.